Dermira has signed a licensing agreement with Roche to secure exclusive rights to lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications.
Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
The Association of the British Pharmaceutical Industry (ABPI) has applied for judicial review over new procedures that restrict access to cost-effective medicines.
Pfizer has broke ground on a research and development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield in the US state of Missouri.
Eli Lilly and Company has completed the $90m expansion of its biotechnology center in San Diego, California, US.
Bristol-Myers Squibb has agreed to divest its small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to South Korea based SK Biotek, a subsidiary of SK Holdings.
Bristol-Myers Squibb’s Opdivo (nivolumab) has been approved by the European Commission (EC) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-based therapy.
Plant-based ingredient manufacturer Roquette has agreed to buy Brazilian pharmaceutical tablet maker Itacel.
Abzena has entered into a manufacturing agreement with University College London (UCL).
Global healthcare and life science company Arix Bioscience has raised £100m in its Initial Public Offering (IPO) on the main market of the London Stock Exchange.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.